Актовегин: биологический препарат с полувековой историей


Buchmayer F., Pleiner J., Elmlinger M.W., Lauer G., Nell G., Sitte H.H.

Актовегин представляет собой биологический препарат: гемодиализат телячьей крови, который получают из природного источника. В основе его лечебного действия лежит ряд механизмов, приводящих к общему результату: усилению внутриклеточного метаболизма, связанного с инсулиноподобным действием инозитолфосфоолигосахаридов. Актовегин помогает при нарушениях кровообращения и трофики головного мозга, нарушениях периферического кровотока и связанных с этим заболеваниях, трансплантации кожи и лечении ран. В данной статье рассматриваются механизмы действия Актовегина и его активность в различных патологических ситуациях.

Литература


1. Bachmann W, Forster H, Mehnert H. Experimental studies in animals on the effect of a proteinfree blood extract on the metabolism of glucose. Arzneimittel-Forschung/Drug Research 1968;18:1023–27.


2. Parade D, Biro G, Ketti H, et al. Studies on the insulinlike action of a lowmolecular-weight blood extract on the glucose metabolism of isolated adipose tissue of the rat in vitro. Arzneimittel-Forschung/Drug Research 1968;18:1019–21.


3. Saltiel AR, Cuatrecasas P. Insulin stimulates the generation from hepatic plasma membranes of modulators derived from an inositol glycolipid. Proc NatlAcad Sci USA 1986;83:5793–97.


4. Fox JA, Soliz NM, Saltiel AR. Purification of a phosphatidylinositolglycan-specific phospholipase C from liver plasma membranes: a possible target of insulin action. Proc Natl Acad Sci USA1987;84:2663–67.


5. Saltiel AR, Sorbara-Cazan LR. Inositol glycan mimics the action of insulin on glucose utilization in rat adipocytes. Biochem Biophys Res Commun1987;149:1084–92.


6. Mato JM, Kelly KL, Abler A, et al. Identification of a novel insulinsensitive glycophospholipid from H35 hepatoma cells. J Biol Chem 1987;262:2131–37.


7. Kellerer M, Machicao F, Berti L, et al. Inositol phospho-oligosaccharides from rat fibroblasts and adipocytes stimulate 3-O-methylglucose transport. Biochem J 1993;295:699–704.


8. Bachmann H. Wirkung von Actihaemyl auf den Kohlenhydratstoffwechsel–Untersuchungen in vivo; Dissertation, Medizinische Poliklinik der Universitat Munchen, 1968.


9. Obermaier-Kusser B, Muhlbacher C, Mushack J, et al. Further evidence for a two-step model of glucose-transport regulation. Inositol phosphateoligosaccharides regulate glucose-carrier activity. Biochem J, 1989;261:699–705.


10. Mohnike G, Lippmann HG, Dieckmann I, et al. Zur Wirkung eines Extraktes aus Kalberblut im Stoffwechsel der Glucose. Arzneimittel-Forschung/Drug Research 1968;18:1021.


11. Machicao F, Muhlbacher Ch, Haring HU. Inositol phospho-ooligosaccharides from a dialysate (Actovegin) obtained from blood mimic the effect on lipogenesis glucose transport and lipolysis in rat adipocytes. Aktuelle Endokrinologie undStoffwechsel, 1989;10:111.


12. Machicao F, Sixt B, Seffer E, et al. Adipocytes release inositol phosphate oligosaccharides with insulin like activity similarly as found in hemodialysate. IV International Symposium on Insulin Receptor and Insulin Action, Verona, Italy 1990:124.


13. Machicao F, Mushack J, Seffer E, et al. Mannose, glucosamine and inositol monophosphate inhibit the effects of insulin on lipogenesis. Further evidence for a role for inositol phosphate-oligosaccharides in insulin action. Biochem J1990;266:909–16.


14. Suzuki S, Sugawara K, Satoh Y, et al. Insulin stimulates the generation of two putative insulin mediators, inositol-glycan and diacylglycerol in BC3H-1 myocytes. J Biol Chem 1991;266:8115–21.


15. Jager KH, Leybold K, Mittenzwei H, et al. The promotional of cell respiration by a blood extract. Arzneimittel-Forschung/Drug Research, 1965;15:750–54.


16. de Groot H, Brecht M, Machicao F. Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract. Res Commun Chem Pathol Pharmacol 1990; 68:125–28.


17. Brecht M, de Groot H. Protection from hypoxic injury in cultured hepatocytes by glycine, alanine and serine. Amino Acids 1994;6:25–35.


18. Schafer G. Untersuchungsbefund (Report) Wirkung von Actovegin bzw Placebo auf die Sauerstoffaufnahme isolierter Leberparenchym Zellen. Internal Company Report, Institut fur Klinische Biochemie, Medizinische Hochschule Hannover, 1977.


19. Reichel H, Weiss C, Leichtweiss HP. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneimittel-Forschung/Drug Research1965;15:756–57.


20. Kuninaka T, Senga Y, Senga H, et al. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol 1991; 146:148–55.


21. Schwabe K. Experimentelle Untersuchungen mit einem eiweiβfreien Extrakt aus Vollblut von Kalbern mit hoher RES-Aktivitat. Arzneimittel-Forschung/Drug Research 1966;16:364–70.


22. Pichotka J, Jager KH, Pape J, et al. Wirkung eines Blutextraktes auf den Stoffwechsel einfacher Systeme. Arzneimittel-Forschung/Drug Research 1965;15:754.


23. Rammler L. Actihaemyl/ATP-Konzentrationen in Meerschweinchen-Gerhirnhomogenaten. Internal Company Report, Pharmakologische Abteilung Hormon-Chemie Munchen, 1974.


24. Chanh PH, Chanh AP, Basile JP, et al. Cardiovascular activity of a deproteinized blood extract. Arzneimittel-Forschung/Drug Research1980;30:1874–77.


25. Chanh PH, Chanh AP, van Thoai MN, et al. Effects of deproteinized blood extract on respiratory and hemodynamic modifications induced by hypoxia in the anaesthetized animal. Arzneimittel-Forschung/Drug Research 1980;30:1508–10.


26. Neinhardt J. Extra- und intraorale Wundheilung. Dissertation/PhD Thesis, Universitats- und Poliklinik fur Zahn-, Mund-, und Kieferkrankheiten Wurzburg, 1967.


27. Mochida H, Kikuchi T, Tanaka H, et al. Influence of Actovegin containing infusion solutions on wound healing and function of the intestinal tract in rats. Pharmacology and Therapeutics 1989;17:789–97.


28. Schonwald D, Sixt B, Machicao F, et al. Enhanced proliferation of coronary endothelial cells in response to growth factors is synergized by hemodialysate compounds in vitro. Res Exp Med (Berl) 1991;191:259–72.


29. Miltenburger HG, BaschongW, Horner V, et al. Cooperative effects in vitro on fibroblast and keratinocyte functions related to wound healing by transforming growth factor-beta and a low molecular weight fraction from hemolyzed blood. Arzneimittel-Forschung/Drug Research1994;44:872–76.


30. Spessotto P, Dri P, BaschongW, et al. Effect of a protein-free dialysate from calf blood on human monocyte differentiation in vitro. Arzneimittel-Forschung/Drug Research 1993;43:747–51.


31. Bauer D, Locker A. The radioprotective effect of solcoseryl. Experientia 1974;30:643.


32. Barth G, Graebner HF, Lotz H. Therapy of lethal radiation injury with Actihaemyin an animal experiment. Strahlentherapie 1969;138:714–23.


33. Basu SK, Srinivasan MN, Chuttani K, et al. Evaluation of some radioprotectors by the survival study of rats exposed to lethal dose of whole body gamma radiation. J Radiat Res (Tokio),1985;26:395–403.


34. Tamou S, Trott KR. Modification of late radiation damage in the rectum of rats by deproteinized calf blood serum (ActoHorm) and pentoxifylline (PTX). Strahlenther Onkologie 1994;170:415–20.


35. Sigdestad CP, Doak KW, Grdina DJ. Differential protection of radiation-induced DNA single-strand breaks and cell survival by solcoseryl. Experientia 1988;44:707–8.


36. Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care2009;32:1479–84.


37. Wolff VR. Effect of a protein-free hemoderivative on recovering capability of rat liver following 60 minutes of hemorrhagic shock. Arzneimittel-Forschung/Drug Research 1975;25:388–92.


38. Giarola P. Effects of blood extract on plasma lipids, blood coagulation, fibrinolysis and platelet aggregation in experimental hypercholesterolemia of rabbits. Arzneimittel-Forschung/Drug Research 1974;24:925–28.


39. Somogyi E, Sotonyi P, Nemes A. The effects of a deproteinized blood extract on the myocardial changes developing during experimentally induced intermittent hypoxia. Arzneimittel-Forschung/Drug Research 1979;29:1376–81.


40. Eichler K, Volker R. Cardiotonic effect of blood extracts on myocardial tissue; in Cardiotonische Wirkung von Blutextrakten auf das Herzmuskelgewebe. Arzneimittel-Forschung/Drug Research 1971;21:1750–52.


41. Lanner G, Argyropoulos G. Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research. Wien Med Wochenschrift 1975;125:681–85.


42. Kruger G, Quadbeck G. The electroencephalogram of the rat in oxygen deficiency as an indicator of drug effects on cerebral metabolism. Arzneimittel-Forschung/Drug Research 1972;22:451–56.


43. Quadbeck G, Claver B, Minet G. The influence of stimulants and antidepressants on the EEG amplitude in the rat. Arzneimittelforschung 1964;14(5).


44. Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Arch Gerontol Geriatr,1989;9:181–92.


45. Mintz M, Knowlton B, Myslobodsky MS. Effect of nootropic Solcoseryl on kainic acid-induced excitotoxic brain injury. Pharmacol Biochem Behav 1993;45:55–8.


46. Schaffler K, Wauschkuhn CH, Hauser B. Study to evaluate the encephalotropic potency of a hemodialysate. Controlled study using electroretinography and visual evoked potentials under hypoxic conditions in human volunteers (preliminary communication). Arzneimittelforschung1991;41:699–704.


47. Saletu B, Grunberger J, Linzmayer L, et al. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative Actovegin: doubleblind, placebo-controlled trials. Neuropsychobiology1990;24:135–48.


48. Semlitsch HV, Anderer P, Saletu B, et al. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology1990;24:49–56.


Об авторах / Для корреспонденции


1 Center for Physiology and Pharmacology, Institute of pharmacology, Medical University of Vienna, Vienna, Austria
2 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
3 Nycomed GmbH, Biomarker Development, Konstanz, Germany


Похожие статьи


Бионика Медиа